AOD 9604 is a recurring topic in our peptide coverage. This hub collects every article tagged AOD 9604, newest first, each evidence-graded and tied to real, verifiable sources.
An evidence-graded review of the peptides marketed for osteoarthritis and joint degeneration. The honest 2026 verdict: the strongest human data belongs not to any joint-repair peptide but to GLP-1 metabolic drugs that relieve knee-OA pain by removing mechanical load.
An evidence-graded review of the peptides marketed for endurance and aerobic performance — elamipretide (SS-31), MOTS-c and AOD-9604. The honest 2026 verdict: no peptide is proven to raise VO₂max or race performance in healthy humans, the category is preclinical-dominant, and MOTS-c is WADA-banned at all times.
An evidence-graded ranking of the peptides marketed for cellulite — oral collagen peptides, GHK-Cu, AOD-9604 and HGH Fragment 176-191 — separating the one modest human signal from mechanism, marketing and WADA-banned research chemicals.
An evidence-graded review of the peptides marketed for cartilage and meniscus repair. The honest 2026 verdict: no peptide has a placebo-controlled human trial showing cartilage regrowth or meniscus repair, and the only controlled human data belongs to pentosan polysulfate — which is not even a peptide.
A clinical monograph on HGH Fragment 176-191 — the C-terminal 'lipolytic tail' of growth hormone sold as a fat-loss peptide. No human RCTs, an antilipogenic animal mechanism, and a closely related analogue (AOD-9604) that failed its pivotal obesity trial.
A clinical monograph on AOD-9604 — the hGH-fragment fat-loss peptide that completed six human RCTs and largely failed to beat placebo. Strong safety data, a failed pivotal weight-loss trial, and an unsettled 2026 legal status.
AOD 9604 is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged AOD 9604, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.